These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 7545085

  • 1. Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation.
    Chari RV, Jackel KA, Bourret LA, Derr SM, Tadayoni BM, Mattocks KM, Shah SA, Liu C, Blättler WA, Goldmacher VS.
    Cancer Res; 1995 Sep 15; 55(18):4079-84. PubMed ID: 7545085
    [Abstract] [Full Text] [Related]

  • 2. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA, Halloran PM, Ferris CA, Levine BA, Bourret LA, Goldmacher VS, Blättler WA.
    Cancer Res; 1993 Mar 15; 53(6):1360-7. PubMed ID: 7680284
    [Abstract] [Full Text] [Related]

  • 3. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
    Vallera DA, Todhunter DA, Kuroki DW, Shu Y, Sicheneder A, Chen H.
    Clin Cancer Res; 2005 May 15; 11(10):3879-88. PubMed ID: 15897589
    [Abstract] [Full Text] [Related]

  • 4. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
    Lopes de Menezes DE, Pilarski LM, Allen TM.
    Cancer Res; 1998 Aug 01; 58(15):3320-30. PubMed ID: 9699662
    [Abstract] [Full Text] [Related]

  • 5. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.
    Griffiths GL, Mattes MJ, Stein R, Govindan SV, Horak ID, Hansen HJ, Goldenberg DM.
    Clin Cancer Res; 2003 Dec 15; 9(17):6567-71. PubMed ID: 14695162
    [Abstract] [Full Text] [Related]

  • 6. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
    de Kroon JF, de Paus RA, Kluin-Nelemans HC, Kluin PM, van Bergen CA, Munro AJ, Hale G, Willemze R, Falkenburg JH.
    Exp Hematol; 1996 Jul 15; 24(8):919-26. PubMed ID: 8690051
    [Abstract] [Full Text] [Related]

  • 7. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
    Tassone P, Gozzini A, Goldmacher V, Shammas MA, Whiteman KR, Carrasco DR, Li C, Allam CK, Venuta S, Anderson KC, Munshi NC.
    Cancer Res; 2004 Jul 01; 64(13):4629-36. PubMed ID: 15231675
    [Abstract] [Full Text] [Related]

  • 8. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma.
    DiJoseph JF, Goad ME, Dougher MM, Boghaert ER, Kunz A, Hamann PR, Damle NK.
    Clin Cancer Res; 2004 Dec 15; 10(24):8620-9. PubMed ID: 15623646
    [Abstract] [Full Text] [Related]

  • 9. Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons.
    Michel RB, Rosario AV, Andrews PM, Goldenberg DM, Mattes MJ.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):777-86. PubMed ID: 15701868
    [Abstract] [Full Text] [Related]

  • 10. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R, Desjarlais JR, Zhukovsky EA.
    Cancer Res; 2008 Oct 01; 68(19):8049-57. PubMed ID: 18829563
    [Abstract] [Full Text] [Related]

  • 11. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
    Bonardi MA, French RR, Amlot P, Gromo G, Modena D, Glennie MJ.
    Cancer Res; 1993 Jul 01; 53(13):3015-21. PubMed ID: 7686448
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV.
    Acc Chem Res; 2008 Jan 01; 41(1):98-107. PubMed ID: 17705444
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
    Flavell DJ, Boehm DA, Noss A, Warnes SL, Flavell SU.
    Br J Cancer; 2001 Feb 01; 84(4):571-8. PubMed ID: 11207056
    [Abstract] [Full Text] [Related]

  • 17. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs.
    Sapra P, Allen TM.
    Cancer Res; 2002 Dec 15; 62(24):7190-4. PubMed ID: 12499256
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer.
    Zhao RY, Erickson HK, Leece BA, Reid EE, Goldmacher VS, Lambert JM, Chari RV.
    J Med Chem; 2012 Jan 26; 55(2):766-82. PubMed ID: 22148292
    [Abstract] [Full Text] [Related]

  • 19. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
    Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany-Amorim C.
    Clin Cancer Res; 2009 Jun 15; 15(12):4038-45. PubMed ID: 19509168
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.